ClinicalTrials.gg
CompletedNCT01453946Updated Jan 6, 2022Results posted

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

A Phase 3 interventional study of Entocort in Crohn's Disease, sponsored by Padagis LLC. Completed at 19 sites in 5 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-01-06.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
274th of 528
55 · median 60
Started
2011
with 32 others
Phase 3
124 of 660
21 open now
Registered
194th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 274th largest by enrollment of the 528 interventional ones that give a count, is one of 33 that started in 2011, is one of 124 in phase 3, and was the 194th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

A Safety for Maintenance of Entocort EC for children with mild to moderate Crohn's Disease.

Read the detailed description

A Multicenter, Open label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit.
  • All subjects must weight >= 15 kg at the time of enrollment.
  • Subjects must have been diagnosed and treated for active Crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology and have a PCDAI \<= 10

Exclusion criteria

Exclusion Criteria:

  • Subjects who have had any previous intestinal resection proximal to and including the ascending colon.
  • Subjects with evidence of active Crohn's disease (PCDAI > 10) and/or stricturing, prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications.
  • Subjects with morning cortisol level \<150 nmol/l (5.4 ug/dl) or DHEA-S below normal range for age and gender (NOTE: Subjects from the induction protocol with abnormal morning cortisol/DHEA-S levels at Visit 4, who otherwise meet the eligibility criteria, may be enrolled if the investigator decides that Entocort 6 mg is an appropriate therapy option.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Other
    Entocort

    Study Medication

    Drug: Entocort

Interventions

  • Entocort capsules, taken orally, 6 mg daily.

06

What researchers measure

Primary outcomes

  1. Adverse Event

    Any kind of adverse event

    Time frame: 16 weeks

Secondary outcomes

  1. PCDAI

    Pediatric Crohn's Disease Activity Index. The scale ranges from 0 (no activity) to 100 (high activity)

    Time frame: 12 weeks

  2. IMPACT 3

    IMPACT-III - A QUALITY OF LIFE QUESTIONNAIRE FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE

    Time frame: 12 weeks

07

Results

Posted Jun 19, 2015

Participant flow

In this study, 55 patients were enrolled but only 50 fulfilled the enrolment criteria.

Participant flow — Overall Study
MilestoneEntocort
Started50
Completed41
Not completed9
Withdrew: Did not receive drug for the taper phase1
Withdrew: Protocol violation2
Withdrew: Lack of efficacy3
Withdrew: Adverse event3

Outcome measures

SecondaryPCDAI

Pediatric Crohn's Disease Activity Index. The scale ranges from 0 (no activity) to 100 (high activity)

Time frame:
12 weeks
Reported as:
Mean · Scores on a scale
PCDAI
Scores on a scaleEntocort
Baseline4.9 ± 3.6
Change after 12 weeks2.0 ± 7.0
12 weeks6.9 ± 8.1
SecondaryIMPACT 3

IMPACT-III - A QUALITY OF LIFE QUESTIONNAIRE FOR CHILDREN WITH INFLAMMATORY BOWEL DISEASE

Time frame:
12 weeks
Reported as:
Mean · Score units
IMPACT 3
Score unitsEntocort
Baseline146.6 ± 12.4
Change after 12 weeks1.2 ± 8.6
12 weeks147.0 ± 15.5
PrimaryAdverse Event

Any kind of adverse event

Time frame:
16 weeks
Reported as:
Number · Subjects
Adverse Event
SubjectsEntocort
Adverse Event37

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entocort—4/50 (8%)36/50 (72%)
Most frequent serious events
Most frequent serious events
EventEntocort
Crohn's diseaseGastrointestinal disorders3/50
Gastrointestinal haemhorrageGastrointestinal disorders1/50
Ileal stenosisGastrointestinal disorders1/50
Most frequent other events
Showing 10 of 20
Most frequent other events
EventEntocort
Abdominal painGastrointestinal disorders8/50
AcneSkin and subcutaneous tissue disorders6/50
Crohn's diseaseGastrointestinal disorders4/50
Increased appetiteMetabolism and nutrition disorders4/50
IrritabilityGeneral disorders4/50
Mood swingsPsychiatric disorders4/50
CushingoidEndocrine disorders4/50
DyspepsiaGastrointestinal disorders3/50
NasopharyngitisInfections and infestations3/50
Upper respiratory tract infectionInfections and infestations3/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entocort
Mean13.8 (8 to 17)
Age, Customized
Age, Customized(participants)Entocort
<=8 years2
>8 years48
Sex: Female, Male
Sex: Female, Male(Participants)Entocort
Female20
Male30
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Entocort
White45
Black or african american2
Other3
08

Study locations

19 sites
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Oak Lawn, Illinois, United States
  • Research Site
    Newton, Massachusetts, United States
  • Research Site
    Saint Paul, Minnesota, United States
  • Research Site
    Mays Landing, New Jersey, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    München, Germany
  • Research Site
    Nürnberg, Germany
  • Research Site
    Firenze, Italy
  • Research Site
    Messina, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Kraków, Poland
  • Research Site
    Rzeszów, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Wrocław, Poland
  • Research Site
    Łódź, Poland
09

References and documents

Publications

  • Cohen SA, Aloi M, Arumugam R, Baker R, Bax K, Kierkus J, Koletzko S, Lionetti P, Persson T, Eklund S. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children. Curr Med Res Opin. 2017 Jul;33(7):1261-1268. doi: 10.1080/03007995.2017.1313213. Epub 2017 Apr 19. PubMed 28420280 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2011
First posted
Oct 18, 2011
Start
Dec 2011
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Jun 19, 2015
Last update
Jan 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01453946
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Oct 18, 2011
Start date
Dec 2011
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Jun 19, 2015
Last update
Jan 6, 2022

Study contacts

Stanley Cohen, MD
principal investigator · Children's Center for Digestive Healthcare, LLC, Atlanta, Georgia, USA
Stefan Eklund, MD
study director · AstraZeneca Pharmaceuticals, Mölndal, Sweden
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion